Menu
Recruiting NCT04212468

Home Blood Pressure Monitoring Registration Study in the Elderly(HOME Study)

— Observational Blood Pressure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: no intervention.
Who it may be relevant to
Registry conditions: Blood Pressure. Basic parameters: from 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Home Blood Pressure Registration Study on Community Elderly Population(HOME Study)

Overview

China is entering an aging society. As the number of elderly population continues to increase, the elderly are facing many social problems that deserve the attention of all sectors of society. Hypertension is one of the common diseases in the elderly population. Hypertension is the most common chronic diseases and a most important risk factor for cardiovascular and cerebrovascular diseases, and also a substantial public health problem. Home blood pressure monitoring is simple, not only can find hypertension, but also can guide the treatment of patients with hypertension. The purpose of the study is to investigate the association between home blood pressure and adverse outcomes in community elderly population.

Detailed description

Study population includes subjects who living in community, of any race or ethnicity, 65 or older years of age, and have provided written informed consent to provide home blood pressure monitoring at one or more study visits.

Physical examination, questionnaire survey and biological sample collection will be conducted at baseline and the incidence of a composite of major adverse cardiovascular events will be investigated during follow-up.

Interventions

  • Other no intervention
    no intervention

Primary outcome measures

  • All-Cause Mortality [Time frame: From date of inclusion until the date of death from any cause, assessed up to 1 year]
  • Cardiovascular Mortality [Time frame: From date of inclusion until the date of death from any cause, assessed up to 1 year]
Secondary outcome measures (5)
  • Secondary outcomes of cardiovascular diseases [Time frame: Through study completion, an average of 1 years]
  • Secondary outcomes of cerebrovascular diseases [Time frame: Through study completion, an average of 1 years]
  • Secondary outcomes of kidney [Time frame: Through study completion, an average of 1 years]
  • Secondary outcomes of hypertension [Time frame: Through study completion, an average of 1 years]
  • Secondary outcomes of diabetes [Time frame: Through study completion, an average of 1 years]

Eligibility criteria

Inclusion criteria

•≥65 years old

  • Signed informed consent
  • Life expectancy is greater than 1 year

Exclusion criteria

  • <65 years old
  • Unsigned informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 2 centers
  • Feng Yingqing — Guangzhou
  • Guangdong Provincial People's Hospital — Guangzhou

Identifiers

NCT: NCT04212468 · 2018300H(R1)

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗